Target Gene/Pathway Pathway / Gene
Search results
Showing 1 to 10 of 96 entries
| No. | KEGG GENES | KEGG PATHWAY | KEGG DRUG | DrugBank | 指定難病告示番号 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
HRH3
💬1. HRH3
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | Pitolisant
Pitolisant
💬1. HRH3
| Pitolisant | 3件: 6 6, 113, 193 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 |
MAPK14
💬2. MAPK14
| 62件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, Adrenergic signaling in cardiomyocytes, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis 62件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, S ... | Losmapimod
Losmapimod
💬2. MAPK14
| Losmapimod | 2件: 113 113, 222 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 |
CSF3R
💬3. CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, ... | Filgrastim
Filgrastim
💬3. CSF3R
| Filgrastim | 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 35件: 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 6 ... 3. CSF3R
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 |
ADRA1D
💬4. ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Carvedilol
Carvedilol
💬4. ADRA1D
| Carvedilol | 4件: 57 57, 86, 113, 210 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 |
ADRA1B
💬5. ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Carvedilol
Carvedilol
💬5. ADRA1B
| Carvedilol | 4件: 57 57, 86, 113, 210 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 |
ADRA1A
💬6. ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, ... | Carvedilol
Carvedilol
💬6. ADRA1A
| Carvedilol | 4件: 57 57, 86, 113, 210 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 |
CCN2
💬7. CCN2
| 2件: Apelin signaling pathway Apelin signaling pathway, Hippo signaling pathway | Pamrevlumab
Pamrevlumab
💬7. CCN2
| Pamrevlumab | 2件: 85 85, 113 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 |
ADRA2A
💬8. ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬8. ADRA2A
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬8. ADRA2A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 |
ADRA2B
💬9. ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬9. ADRA2B
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬9. ADRA2B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 |
ADRA2C
💬10. ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬10. ADRA2C
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬10. ADRA2C
|